EXACT SCIENCES CORP 8-K

What Happened
Exact Sciences Corp (EXAS) announced in an 8-K filed March 20, 2026 that it entered into a merger agreement with Abbott Laboratories and Badger Merger Sub I, Inc. on November 19, 2025. Under the agreement, Merger Sub will merge with and into Exact, and Exact will survive as a direct, wholly owned subsidiary of Abbott. Exact’s stockholders approved the transaction at a special meeting on February 20, 2026, and the parties reported that all required regulatory approvals and clearances had been received as of March 19, 2026. The merger is anticipated to close on March 23, 2026, subject to remaining closing conditions.

Key Details

• Merger Agreement date: November 19, 2025 (parties: Exact, Abbott, Badger Merger Sub I, Inc.).
• Stockholder approval: Special meeting held February 20, 2026.
• Regulatory status: All required regulatory approvals and clearances received as of March 19, 2026.
• Expected closing date: March 23, 2026, subject to satisfaction or waiver of remaining conditions.

Why It Matters
This transaction will make Exact Sciences a direct, wholly owned subsidiary of Abbott, representing a major corporate change that can affect shareholders, management, employees, customers and partners. The filing underscores that closing remains subject to remaining conditions and lists typical merger risks (e.g., possibility the deal may not close, potential termination fees, contractual restrictions, transaction costs, and possible effects on stock price and personnel). Investors should note the expected close date and the company’s reminder of forward-looking risks, and monitor for any updates or official closing notice.